Dyax Corp. and Sigma-Tau Group Expand Agreement to Commercialize KALBITOR(R) (ecallantide) for Hereditary Angioedema
Published: Jan 11, 2011
(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) and Defiante Farmaceutica S.A., an affiliate of the pharmaceutical group Sigma-Tau (Sigma-Tau), announced today the expansion of their partnership to commercialize KALBITOR® (ecallantide) for the treatment of hereditary angioedema (HAE) throughout Australia and New Zealand. Defiante already has rights to KALBITOR for Europe, North Africa, Middle East and Russia, while Dyax retains the rights to develop and commercialize KALBITOR in the U.S. and in other un-partnered territories. KALBITOR was approved by the U.S. Food and Drug Administration (FDA) in December 2009 and is marketed by Dyax for the treatment of acute attacks of HAE in patients 16 years of age and older.